MX346379B - Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. - Google Patents

Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.

Info

Publication number
MX346379B
MX346379B MX2013011693A MX2013011693A MX346379B MX 346379 B MX346379 B MX 346379B MX 2013011693 A MX2013011693 A MX 2013011693A MX 2013011693 A MX2013011693 A MX 2013011693A MX 346379 B MX346379 B MX 346379B
Authority
MX
Mexico
Prior art keywords
dependent kinase
cyclin dependent
inhibitor
cdk4
combination
Prior art date
Application number
MX2013011693A
Other languages
English (en)
Inventor
Borland Maria
Thomas Brain Christopher
Doshi Shivang
Kim Sunkyu
Ma Jianguo
Murtie Josh
Zhang Hong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346379(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX346379B publication Critical patent/MX346379B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una combinación de un inhibidor de CDK4/6 y un inhibidor de mTOR para el tratamiento de cáncer.
MX2013011693A 2010-04-13 2012-10-12 Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer. MX346379B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32354110P 2010-04-13 2010-04-13

Publications (1)

Publication Number Publication Date
MX346379B true MX346379B (es) 2017-03-16

Family

ID=44146770

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012011912A MX2012011912A (es) 2010-04-13 2011-04-12 Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
MX2013011693A MX346379B (es) 2010-04-13 2012-10-12 Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012011912A MX2012011912A (es) 2010-04-13 2011-04-12 Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.

Country Status (11)

Country Link
US (3) US20130035336A1 (es)
EP (1) EP2558092B1 (es)
JP (1) JP5918214B2 (es)
KR (1) KR101830455B1 (es)
CN (1) CN102869358B (es)
AU (1) AU2011240735B2 (es)
CA (1) CA2800327A1 (es)
ES (1) ES2689177T3 (es)
MX (2) MX2012011912A (es)
RU (1) RU2589696C2 (es)
WO (1) WO2011130232A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020675A1 (en) 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
CA2891938A1 (en) * 2012-11-28 2014-06-05 Novartis Ag Combination therapy
WO2014130932A2 (en) 2013-02-25 2014-08-28 Novartis Ag Novel androgen receptor mutation
JP2016512831A (ja) 2013-03-15 2016-05-09 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたパルボシクリブ
BR112016002465B1 (pt) * 2013-08-14 2022-09-20 Novartis Ag Combinação farmacêutica e seu uso
CN106029099A (zh) * 2013-08-28 2016-10-12 诺华股份有限公司 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CA2954189A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP3778604A1 (en) * 2015-02-13 2021-02-17 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN107428731B (zh) * 2015-03-11 2020-05-05 正大天晴药业集团股份有限公司 作为抗癌药物的取代的2-氢-吡唑衍生物
EP3156406A1 (en) * 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US20190175598A1 (en) * 2016-08-23 2019-06-13 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
BR112019012176A2 (pt) 2016-12-16 2019-11-05 Cstone Pharmaceuticals composto, sal farmaceuticamente aceitável do mesmo ou isômero do mesmo, uso dos mesmos e composição farmacêutica
JOP20190151B1 (ar) 2016-12-20 2023-09-17 Astrazeneca Ab مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
EA201992253A1 (ru) 2017-03-23 2020-03-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
AU2018354972B2 (en) 2017-10-27 2021-07-08 Fresenius Kabi Oncology Ltd. An improved process for the preparation of ribociclib and its salts
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2019222524A1 (en) * 2018-05-16 2019-11-21 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidines as pan-tam inhibitors and their application in cancer treatment
JP7382353B2 (ja) 2018-06-15 2023-11-16 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体およびその使用
US20220096482A1 (en) * 2018-09-10 2022-03-31 Mirati Therapeutics, Inc. Combination therapies
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US20220056037A1 (en) * 2018-12-28 2022-02-24 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
EP3902805A4 (en) * 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLIN DEPENDENT KINASE INHIBITORS
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN112094272A (zh) * 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
CN115209897A (zh) 2019-12-05 2022-10-18 安纳库利亚治疗公司 雷帕霉素类似物及其用途
BR112022011758A2 (pt) * 2019-12-16 2022-08-30 Lunella Biotech Inc Terapêutica de câncer inibidor de cdk4/6 seletivo
WO2021133886A1 (en) 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
JP2024503898A (ja) * 2021-01-22 2024-01-29 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体及びその使用
KR20220147511A (ko) 2021-04-27 2022-11-03 재단법인 아산사회복지재단 사이클린 의존성 키나아제 억제용 조성물 및 이의 의학적 용도
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE60010098T2 (de) 1999-08-24 2005-03-31 Ariad Gene Therapeutics, Inc., Cambridge 28-epirapaloge
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
BRPI0511967B8 (pt) * 2004-06-11 2021-05-25 Japan Tobacco Inc derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina, seu uso e composição farmacêutica que os compreende
KR20070108916A (ko) 2005-02-25 2007-11-13 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도
WO2006090169A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
CN102579467A (zh) * 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
JP5335432B2 (ja) 2005-11-17 2013-11-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 縮合２環系ｍＴＯＲ阻害剤
CA2628920C (en) 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
EP1979325A1 (en) 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US7480581B2 (en) 2006-06-27 2009-01-20 Teradyne, Inc. Calibrating a testing device
US20100004243A1 (en) 2006-07-14 2010-01-07 Astex Therapeutics Limited Pharmaceutical compounds
JP5227321B2 (ja) 2006-08-23 2013-07-03 クドス ファーマシューティカルズ リミテッド Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
CA2707989A1 (en) * 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
WO2010020675A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
AU2010243353B2 (en) 2009-04-30 2014-09-11 Astex Therapeutics Limited Imidazole derivatives and their use as modulators of Cyclin dependent Kinases
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6

Also Published As

Publication number Publication date
EP2558092B1 (en) 2018-06-27
WO2011130232A1 (en) 2011-10-20
CN102869358A (zh) 2013-01-09
US20130035336A1 (en) 2013-02-07
KR20130098151A (ko) 2013-09-04
RU2589696C2 (ru) 2016-07-10
MX2012011912A (es) 2012-11-16
CA2800327A1 (en) 2011-10-20
JP5918214B2 (ja) 2016-05-18
JP2013523885A (ja) 2013-06-17
US20160008367A1 (en) 2016-01-14
US20180207163A1 (en) 2018-07-26
AU2011240735B2 (en) 2015-01-29
EP2558092A1 (en) 2013-02-20
AU2011240735A1 (en) 2012-11-01
CN102869358B (zh) 2016-03-23
ES2689177T3 (es) 2018-11-08
RU2012148133A (ru) 2014-05-20
KR101830455B1 (ko) 2018-02-20

Similar Documents

Publication Publication Date Title
MX346379B (es) Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (cdk4/6) y un inhibidor de mtor para tratar cancer.
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
EA201171367A1 (ru) Винилиндазолильные соединения
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MY191825A (en) Therapeutic compounds and compositions
MX355543B (es) Macrociclos peptidomiméticos.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
AU2011274510A8 (en) Combinations of kinase inhibitors for the treatment of cancer
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
IN2012DN03012A (es)
MX2011006290A (es) Compuestos de aza-azuleno.
MX2012004286A (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
TN2011000298A1 (en) Compounds useful for inhibiting chk1
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
WO2012073047A3 (en) Compositions and methods
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
EP3113775A4 (en) Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2013015357A (es) Terapia de combinacion.
WO2008121467A3 (en) Combination therapy for treating cancer